dextromethorphan hydrobromide


Also found in: Dictionary, Encyclopedia.

dextromethorphan hydrobromide

Adult Dry Cough (UK), Balminil DM (CA), Broncho-Grippol-DM (CA), Calmylin #1 (CA), Creo-Terpin, Creomulsion, Delsym, DexAlone, Hold DM, Koffex-DM (CA), Neo-DM (CA), Robitussin Children's Cough Long-Acting, Robitussin for Dry Coughs (UK), Robitussin Maximum Strength Cough Suppressant, Scot-Tussin Diabetes, Sedatuss (CA), Triaminic Children's Long-Acting Cough, Trocal, Vicks DayQuil Cough, Vicks Vaposyrup for Dry Cough (UK), Vicks 44 Cough Relief

Pharmacologic class: Levorphanol derivative

Therapeutic class: Antitussive (nonnarcotic)

Pregnancy risk category C

Action

Depresses cough reflex through direct effect on cough center in medulla. Has no expectorant action and does not inhibit ciliary action. Although related to opioids structurally, lacks analgesic and addictive properties.

Availability

Gelcaps: 15 mg, 30 mg

Liquid: 3.5 mg/5 ml, 5 mg/5 ml, 7.5 mg/5 ml, 15 mg/5 ml

Lozenges: 5 mg, 7.5 mg

Oral suspension (extended-release): 30 mg/5 ml

Syrup: 7.5 mg/5 ml, 10 mg/15 ml

Indications and dosages

Cough caused by minor viral upper respiratory tract infections or inhaled irritants

Adults and children over age 12: 10 to 20 mg P.O. q 4 hours, or 30 mg P.O. q 6 to 8 hours, or 60 mg of extended-release form P.O. b.i.d. (not to exceed 120 mg/day)

Children ages 6 to 12: 5 to 10 mg P.O. q 4 hours, or 15 mg P.O. q 6 to 8 hours, or 30 mg of extended-release form P.O. q 12 hours (not to exceed 60 mg/day)

Children ages 4 to 6: 2.5 to 7.5 mg (syrup) P.O. q 4 to 8 hours or 15 mg (extended-release form) P.O. b.i.d. Not to exceed 30 mg/day.

Dosage adjustment

• Elderly patients

Contraindications

• Hypersensitivity to drug

• Chronic productive cough

• MAO inhibitor use within past 14 days

Precautions

Use cautiously in:

• tartrazine sensitivity

• diabetes mellitus (with sucrose-containing drug products)

• pregnant or breastfeeding patients

• children younger than age 2 (safety not established).

Administration

• Don't administer lozenges to children younger than age 6.

Don't give within 14 days of MAO inhibitors.

Adverse reactions

CNS: dizziness and sedation

GI: nausea, vomiting, stomach pain

Interactions

Drug-drug. Amiodarone, fluoxetine, quinidine: increased dextromethorphan blood level, greater risk of adverse reactions

Antidepressants, antihistamines, opioids, sedative-hypnotics: additive CNS depression

MAO inhibitors, sibutramine: serotonin syndrome (nausea, confusion, blood pressure changes)

Drug-behaviors. Alcohol use: additive CNS depression

Patient monitoring

• Monitor cough frequency and type, and assess sputum characteristics.

• Assess hydration status. Increase patient's fluid input to help moisten secretions.

Patient teaching

• Advise patient to avoid irritants, such as smoking, dust, and fumes. Suggest use of humidifier to filter air pollutants.

• Inform patient that treatment aims to decrease coughing frequency and intensity without completely eliminating protective cough reflex.

• Instruct patient to contact health care provider if cough lasts more than 7 days.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

dex·tro·meth·or·phan hy·dro·bro·mide

(deks'trō-meth-ōr'fan hī'drō-brō'mīd),
A synthetic morphine derivative used as an antitussive agent. Inferior to codeine but does not seem to create physical dependence. It has weak central depressant action.

dex·tro·meth·or·phan hy·dro·bro·mide

(deks'trō-mĕ-thōr'fan hī'drō-brō'mīd)
A synthetic morphine derivative used as an antitussive agent. Inferior to codeine but does not seem to create physical dependence. It has weak central depressant action.
Mentioned in ?
References in periodicals archive ?
In group A there were 9 out of 11 (81.8%) patients who had very severe cough, using a dextromethorphan hydrobromide. On the other hand, in group B there were 6 out of 8 (75.0%) patients.
Biopharmaceutical company Avanir Pharmaceuticals Inc (NasdaqGS:AVNR) said on Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended NUEDEXTA's (dextromethorphan hydrobromide and quinidine sulfate) approval for treating pseudobulbar affect (PBA), irrespective of neurologic cause.
Envelopes sodium bicarbonate 2.18g, 0.88g magnesium sulfate, saccharin 2.50mg,325mg tablets of acetylsalicylic acid, 2 mg chlorpheniramine maleate, hydrobromide fenilfrina bitrate 8mg, 10mg dextromethorphan hydrobromide,tablets of sodium bicarbonate, citric acid and aspirin
NUEDEXTA is an innovative combination of two well-characterised components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations.
11 different drugs, including m.in .: Ac.Tranexanici, Acetylcysteine, Adenosine, Alfuzosin Hydrochloride, ambenonim chloride, Amisulpride, Atenolol, Betaxolol Hydrochloride, Calcium Polystyrene sulfonate, ciprofibrate, Dextromethorphan Hydrobromide + Dexpanthenol, Dextromethorphan Hydrobromide, Dinoprost, Drotaverine hydrochloride , Isosorbide mononitrate, Milrinone, polystyrene sulfonate Natrii, Natrii Valproas + Acidii Valproicii, Natrii Valproas, Oxybutynin hydrochloride, Phospholipidum essential, Ranitidine, Sotaloli h / chlorine.
Technology based specialty pharmaceutical company Impax Laboratories Inc (Nasdaq:IPXL) on Wednesday confirmed that it has initiated a challenge of the patents listed in connection with Nuedexta (dextromethorphan hydrobromide and quinidine sulfate 20 mg / 10 mg) capsules.
The company said it plans to use the net proceeds from this offering for sales and marketing activities relating to its newly approved product NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate).
Biopharmaceutical company Avanir Pharmaceuticals Inc (Nasdaq:AVNR) on Friday announced that the US Food and Drug Administration (FDA) website indicates that an Abbreviated New Drug Application (ANDA) for a generic version of NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) capsules was submitted on 7 March 2011.
AVANIR's total operating expenses for the quarter increased to USD13.9m, from USD6.3m in the first quarter of fiscal 2010, which was primarily attributed to costs incurred in preparation for the commercial launch of NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), the first treatment for pseudobulbar affect.
Net proceeds from this offering will be used by Avanir for sales and marketing activities relating to its newly approved product NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), for further clinical, regulatory and commercial development of NUEDEXTA, as potential business development activities and for general working capital.
The proceeds will be used for sales and marketing activities relating to AVANIR's newly approved product NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate).
The net proceeds will be used by the company for sales and marketing activities relating to its newly approved product NUEDEXTAT (dextromethorphan hydrobromide and quinidine sulfate).